Replies to post #318121 on Amarin Corp Plc (AMRN)

[CaptBeer]

I’m getting good vibes about the possibility for updated ACC Guidelines for VASCEPA in this re-write up of REDUCE-IT in JACC last week! This could also portray the EMA Label not including any TG criteria. WOW! That would be HUGE!

“These are very interesting findings and come on the heels of several negative trials with n–3 fatty acid supplementation. One aspect of this medication is that it has a higher dose of purified EPA (4 g/day) than what was tested in other clinical trials. Other trials with moderate to high doses of EPA are ongoing. This is one of the first non-LDL targeted trials to show a CV benefit and will likely be featured in future guidelines.”